SE421922B - Forfarande for framstellning av derivat av 5-karboxi-(respektive 6-karboxi)4,5,6,7,-tetrahydro-tieno(2,3-c)-(respektive(3,2-c)-)pyridin - Google Patents

Forfarande for framstellning av derivat av 5-karboxi-(respektive 6-karboxi)4,5,6,7,-tetrahydro-tieno(2,3-c)-(respektive(3,2-c)-)pyridin

Info

Publication number: SE421922B
Authority: SE; Sweden
Prior art keywords: formula; derivative; acid; hydrogen; carboxy
Prior art date: 1977-01-07

Application number

SE7714940A

Other languages

English (en)

Swedish (sv)

Other versions

SE7714940L (sv

Inventor

J-P Maffrand

Original Assignee

Parcor

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-01-07

Filing date

1977-12-30

Publication date

1982-02-08

1977-12-30 Application filed by Parcor filed Critical Parcor

1978-07-08 Publication of SE7714940L publication Critical patent/SE7714940L/xx

1982-02-08 Publication of SE421922B publication Critical patent/SE421922B/sv

Links

238000000034 method Methods 0.000 title claims description 42
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title description 33
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
150000001875 compounds Chemical class 0.000 claims description 32
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 28
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 22
229910000041 hydrogen chloride Inorganic materials 0.000 claims description 22
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 8
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 8
238000006243 chemical reaction Methods 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 7
150000004820 halides Chemical class 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 5
150000002431 hydrogen Chemical class 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
238000009835 boiling Methods 0.000 claims description 3
229910052736 halogen Inorganic materials 0.000 claims description 3
230000007062 hydrolysis Effects 0.000 claims description 3
238000006460 hydrolysis reaction Methods 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims description 2
239000011230 binding agent Substances 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
239000011707 mineral Substances 0.000 claims description 2
150000007522 mineralic acids Chemical class 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
125000004432 carbon atom Chemical group C* 0.000 claims 2
125000005843 halogen group Chemical group 0.000 claims 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims 1
125000000217 alkyl group Chemical group 0.000 claims 1
125000004093 cyano group Chemical group *C#N 0.000 claims 1
230000032050 esterification Effects 0.000 claims 1
238000005886 esterification reaction Methods 0.000 claims 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
239000003960 organic solvent Substances 0.000 claims 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
150000003222 pyridines Chemical class 0.000 claims 1
239000013078 crystal Substances 0.000 description 30
238000002844 melting Methods 0.000 description 30
230000008018 melting Effects 0.000 description 30
239000000243 solution Substances 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
230000000694 effects Effects 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
241000700159 Rattus Species 0.000 description 7
208000007536 Thrombosis Diseases 0.000 description 7
239000000460 chlorine Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000002585 base Substances 0.000 description 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
235000004279 alanine Nutrition 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
238000010992 reflux Methods 0.000 description 5
-1 sodium hydroxide Chemical class 0.000 description 5
208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
230000002776 aggregation Effects 0.000 description 4
238000004220 aggregation Methods 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
229910002012 Aerosil® Inorganic materials 0.000 description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
102000007327 Protamines Human genes 0.000 description 3
108010007568 Protamines Proteins 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
229960001138 acetylsalicylic acid Drugs 0.000 description 3
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 3
229940073608 benzyl chloride Drugs 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000000601 blood cell Anatomy 0.000 description 3
230000037396 body weight Effects 0.000 description 3
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 3
229960002768 dipyridamole Drugs 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
210000004731 jugular vein Anatomy 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
239000002504 physiological saline solution Substances 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
SAALQYKUFCIMHR-UHFFFAOYSA-N propan-2-ol;2-propan-2-yloxypropane Chemical compound CC(C)O.CC(C)OC(C)C SAALQYKUFCIMHR-UHFFFAOYSA-N 0.000 description 3
229940048914 protamine Drugs 0.000 description 3
102200014657 rs121434437 Human genes 0.000 description 3
235000004400 serine Nutrition 0.000 description 3
229910021653 sulphate ion Inorganic materials 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000002785 anti-thrombosis Effects 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
AINBZKYUNWUTRE-UHFFFAOYSA-N ethanol;propan-2-ol Chemical compound CCO.CC(C)O AINBZKYUNWUTRE-UHFFFAOYSA-N 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000002513 implantation Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
150000003355 serines Chemical class 0.000 description 2
241000894007 species Species 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000002110 toxicologic effect Effects 0.000 description 2
231100000027 toxicology Toxicity 0.000 description 2
238000005303 weighing Methods 0.000 description 2
VOIZSAUUYAGTMS-LURJTMIESA-N (2s)-2-amino-3-thiophen-3-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC=1C=CSC=1 VOIZSAUUYAGTMS-LURJTMIESA-N 0.000 description 1
RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 description 1
RBIGKSZIQCTIJF-UHFFFAOYSA-N 3-formylthiophene Chemical compound O=CC=1C=CSC=1 RBIGKSZIQCTIJF-UHFFFAOYSA-N 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
MSDZLUHQKBFCHC-UHFFFAOYSA-N 4,5,6,7-tetrahydrothieno[3,2-b]pyridine Chemical class C1CCNC2=C1SC=C2 MSDZLUHQKBFCHC-UHFFFAOYSA-N 0.000 description 1
VWYFITBWBRVBSW-UHFFFAOYSA-N 5-chlorothiophene-2-carbaldehyde Chemical compound ClC1=CC=C(C=O)S1 VWYFITBWBRVBSW-UHFFFAOYSA-N 0.000 description 1
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
CQGRLHBOVUGVEA-UHFFFAOYSA-N OOOOOOOOOOOOOOO Chemical compound OOOOOOOOOOOOOOO CQGRLHBOVUGVEA-UHFFFAOYSA-N 0.000 description 1
RRCYYLHJWRYWEI-UHFFFAOYSA-N OOOOOOOOOOOOOOOOOOOOO Chemical compound OOOOOOOOOOOOOOOOOOOOO RRCYYLHJWRYWEI-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
FPWNQPQTICPCOM-UHFFFAOYSA-N acetonitrile;propan-2-ol Chemical compound CC#N.CC(C)O FPWNQPQTICPCOM-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
150000001295 alanines Chemical class 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
229910001516 alkali metal iodide Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
WTOFYLAWDLQMBZ-LURJTMIESA-N beta(2-thienyl)alanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CS1 WTOFYLAWDLQMBZ-LURJTMIESA-N 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
125000004803 chlorobenzyl group Chemical group 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
OYJXTOVLKZDGFK-UHFFFAOYSA-N ethanol;2-propan-2-yloxypropane Chemical compound CCO.CC(C)OC(C)C OYJXTOVLKZDGFK-UHFFFAOYSA-N 0.000 description 1
239000012259 ether extract Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
238000002350 laparotomy Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
210000000713 mesentery Anatomy 0.000 description 1
125000006178 methyl benzyl group Chemical group 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001936 parietal effect Effects 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940125670 thienopyridine Drugs 0.000 description 1
239000002175 thienopyridine Substances 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
238000002627 tracheal intubation Methods 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
210000001631 vena cava inferior Anatomy 0.000 description 1
KMIOJWCYOHBUJS-HAKPAVFJSA-N vorolanib Chemical compound C1N(C(=O)N(C)C)CC[C@@H]1NC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C KMIOJWCYOHBUJS-HAKPAVFJSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SE7714940A 1977-01-07 1977-12-30 Forfarande for framstellning av derivat av 5-karboxi-(respektive 6-karboxi)4,5,6,7,-tetrahydro-tieno(2,3-c)-(respektive(3,2-c)-)pyridin SE421922B (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR7700408A FR2376860A1 (fr)	1977-01-07	1977-01-07	Tetrahydro-4,5,6,7 thieno (2,3-c) et (3,2-c) pyridines, leur procede de preparation et leur application therapeutique

Publications (2)

Publication Number	Publication Date
SE7714940L SE7714940L (sv)	1978-07-08
SE421922B true SE421922B (sv)	1982-02-08

Family

ID=9185247

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE7714940A SE421922B (sv)	1977-01-07	1977-12-30	Forfarande for framstellning av derivat av 5-karboxi-(respektive 6-karboxi)4,5,6,7,-tetrahydro-tieno(2,3-c)-(respektive(3,2-c)-)pyridin

Country Status (31)

Country	Link
US (1)	US4147787A (fr)
JP (1)	JPS6040436B2 (fr)
AR (1)	AR217668A1 (fr)
AT (1)	AT357532B (fr)
AU (1)	AU508277B2 (fr)
BE (1)	BE862695A (fr)
CA (1)	CA1087187A (fr)
CH (1)	CH631179A5 (fr)
DD (1)	DD133673A5 (fr)
DE (1)	DE2800596C2 (fr)
DK (1)	DK147826C (fr)
ES (1)	ES465683A1 (fr)
FI (1)	FI62308C (fr)
FR (1)	FR2376860A1 (fr)
GB (1)	GB1574394A (fr)
GR (1)	GR66061B (fr)
HU (1)	HU175645B (fr)
IE (1)	IE46288B1 (fr)
IL (1)	IL53708A (fr)
LU (1)	LU78816A1 (fr)
MX (1)	MX5274E (fr)
NL (1)	NL184220C (fr)
NO (1)	NO780050L (fr)
NZ (1)	NZ186168A (fr)
PH (1)	PH12856A (fr)
PL (1)	PL118048B1 (fr)
PT (1)	PT67501B (fr)
SE (1)	SE421922B (fr)
SU (1)	SU683625A3 (fr)
YU (1)	YU40023B (fr)
ZA (1)	ZA7833B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE816390A (fr) *	1973-06-15	1974-12-16		Nouvelles mercaptoalcoylpyridines et leurs derives
US4400384A (en) *	1980-10-06	1983-08-23	Sanofi, S.A.	5-o-Cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methanesulfonate and other novel salts thereof
US4448779A (en) *	1981-07-16	1984-05-15	Sanofi	Use of MS salt in geriatric medicine
US4775757A (en) *	1986-09-22	1988-10-04	Ortho Pharmaceutical Corporation	Thienopyridines useful as cardiovascular agents
US4906756A (en) *	1988-05-10	1990-03-06	Syntex (U.S.A.) Inc.	2-(2-nitrovinyl)thiophene reduction and synthesis of thieno[3,2-c]pyridine derivatives
US5342953A (en) *	1991-01-31	1994-08-30	Syntex (U.S.A.) Inc.	N-2-chlorobenzyl-2-oxo and N-2-chlorobenzyl-2,2-dioxo-1,2,3-oxathiazolidine derivatives, their preparation and synthesis of thieno[3,2-c]pyridine derivatives therefrom
DK0581250T3 (da) *	1992-07-31	1999-09-27	Hoechst Ag	Fremgangsmåde til bioteknisk fremstilling af L-thienylalaniner i enantiomerren form ud fra 2-hydroxy-3-thienyl-acrylsyrer o
FR2710495B1 (fr) *	1993-09-28	1995-10-27	Celaflor Gmbh	Dispositif pour effectuer des traitements insecticides, et leur utilisation dans les habitations.
AU1615895A (en)	1994-03-31	1995-10-12	Bristol-Myers Squibb Company	Imidazole-containing inhibitors of farnesyl protein transferase
WO2000001364A1 (fr) *	1998-07-01	2000-01-13	Sun Pharmaceutical Industries Ltd.	Compositions pharmaceutiques stables de derives de thieno [2,3-c] pyridine
WO2001004090A2 (fr) *	1999-07-09	2001-01-18	Ortho-Mcneil Pharmaceutical, Inc.	Tetrahydro-isoquinolines et tetrahydrothienopyridines neurotrophiques, compositions et procedes associes
PL206138B1 (pl) *	2000-12-25	2010-07-30	Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited	Kompozycja farmaceutyczna zawierająca aspirynę oraz zestaw i zastosowanie składników kompozycji

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3823151A (en) *	1968-08-02	1974-07-09	Ciba Geigy Corp	4,5,6,7-tetrahydrothieno(2,3-d)pyridines
FR2215948B1 (fr) *	1973-02-01	1976-05-14	Centre Etd Ind Pharma
US3997545A (en) *	1973-07-23	1976-12-14	Takeda Chemical Industries, Ltd.	Thienopyridine-carboxylic acid derivatives
FR2312246A1 (fr) *	1975-05-28	1976-12-24	Parcor	Derives de la tetrahydro-4,5,6,7 thieno (3,2-c) pyridine, leur procede de preparation et leurs applications
FR2312247A1 (fr) *	1975-05-30	1976-12-24	Parcor	Derives de la thieno-pyridine, leur procede de preparation et leurs applications

1977
- 1977-01-07 FR FR7700408A patent/FR2376860A1/fr active Granted
- 1977-12-22 YU YU3040/77A patent/YU40023B/xx unknown
- 1977-12-27 US US05/864,939 patent/US4147787A/en not_active Expired - Lifetime
- 1977-12-28 IL IL53708A patent/IL53708A/xx unknown
- 1977-12-30 SE SE7714940A patent/SE421922B/sv not_active IP Right Cessation
- 1977-12-30 IE IE2655/77A patent/IE46288B1/en unknown
1978
- 1978-01-02 NL NLAANVRAGE7800034,A patent/NL184220C/xx not_active IP Right Cessation
- 1978-01-03 HU HU78PA1299A patent/HU175645B/hu unknown
- 1978-01-03 GB GB68/78A patent/GB1574394A/en not_active Expired
- 1978-01-04 CH CH7178A patent/CH631179A5/fr not_active IP Right Cessation
- 1978-01-04 GR GR55094A patent/GR66061B/el unknown
- 1978-01-04 ZA ZA00780033A patent/ZA7833B/xx unknown
- 1978-01-04 AT AT6178A patent/AT357532B/de not_active IP Right Cessation
- 1978-01-04 CA CA294,348A patent/CA1087187A/fr not_active Expired
- 1978-01-05 AR AR270641A patent/AR217668A1/es active
- 1978-01-05 LU LU78816A patent/LU78816A1/fr unknown
- 1978-01-05 ES ES465683A patent/ES465683A1/es not_active Expired
- 1978-01-05 DD DD7800203109A patent/DD133673A5/xx not_active IP Right Cessation
- 1978-01-06 AU AU32238/78A patent/AU508277B2/en not_active Expired
- 1978-01-06 BE BE184146A patent/BE862695A/fr not_active IP Right Cessation
- 1978-01-06 DK DK7578A patent/DK147826C/da not_active IP Right Cessation
- 1978-01-06 NZ NZ186168A patent/NZ186168A/xx unknown
- 1978-01-06 SU SU782562904A patent/SU683625A3/ru active
- 1978-01-06 FI FI780048A patent/FI62308C/fi not_active IP Right Cessation
- 1978-01-06 PT PT67501A patent/PT67501B/fr unknown
- 1978-01-06 MX MX786754U patent/MX5274E/es unknown
- 1978-01-06 PL PL1978203863A patent/PL118048B1/pl unknown
- 1978-01-06 NO NO780050A patent/NO780050L/no unknown
- 1978-01-07 DE DE2800596A patent/DE2800596C2/de not_active Expired
- 1978-01-07 JP JP53000787A patent/JPS6040436B2/ja not_active Expired
- 1978-01-09 PH PH20633A patent/PH12856A/en unknown

Also Published As

Publication number	Publication date
DD133673A5 (de)	1979-01-17
ZA7833B (en)	1978-11-29
NZ186168A (en)	1979-10-25
NO780050L (no)	1978-07-10
IE46288B1 (en)	1983-04-20
FR2376860A1 (fr)	1978-08-04
PT67501B (fr)	1979-06-11
PL118048B1 (en)	1981-09-30
SE7714940L (sv)	1978-07-08
JPS6040436B2 (ja)	1985-09-11
LU78816A1 (fr)	1978-06-09
FR2376860B1 (fr)	1979-04-20
PL203863A1 (pl)	1979-03-26
NL184220B (nl)	1988-12-16
NL184220C (nl)	1989-05-16
FI62308B (fi)	1982-08-31
AT357532B (de)	1980-07-10
AU3223878A (en)	1979-07-12
US4147787A (en)	1979-04-03
CA1087187A (fr)	1980-10-07
YU304077A (en)	1982-08-31
BE862695A (fr)	1978-07-06
ATA6178A (de)	1979-12-15
CH631179A5 (fr)	1982-07-30
HU175645B (hu)	1980-09-28
IL53708A0 (en)	1978-03-10
PH12856A (en)	1979-09-12
PT67501A (fr)	1978-02-01
DE2800596C2 (de)	1985-12-12
AR217668A1 (es)	1980-04-15
GB1574394A (en)	1980-09-03
ES465683A1 (es)	1978-10-01
DK147826C (da)	1985-06-10
NL7800034A (nl)	1978-07-11
DK147826B (da)	1984-12-17
DK7578A (da)	1978-07-08
IL53708A (en)	1980-09-16
AU508277B2 (en)	1980-03-13
IE46288L (en)	1978-07-07
DE2800596A1 (de)	1978-07-13
GR66061B (fr)	1981-01-15
FI780048A7 (fi)	1978-07-08
JPS5387394A (en)	1978-08-01
YU40023B (en)	1985-06-30
FI62308C (fi)	1982-12-10
MX5274E (es)	1983-05-31
SU683625A3 (ru)	1979-08-30

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 7714940-9

Effective date: 19901106

Format of ref document f/p: F

Publication	Publication Date	Title
AU2015374118B2 (en)	2020-07-23	Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
UA105758C2 (uk)	2014-06-25	5-членні гетероциклічні аміди та споріднені сполуки
EP1710246A1 (fr)	2006-10-11	Macrocycles de sulfoximine-pyrmidine et leurs sels correspondants, leurs procédé de fabrication, et leurs utilisation pharmaceutique contre le cancer
CA2955059A1 (fr)	2015-01-22	Derives de spiroquinoxaline en tant qu'inhibiteurs de la mort cellulaire regulee non apoptotique
CN101466669A (zh)	2009-06-24	苯基吡咯氨基胍衍生物
KR20200118145A (ko)	2020-10-14	테트라히드로이소퀴놀린계 화합물, 이의 제조 방법, 테트라히드로이소퀴놀린계 화합물을 포함하는 약물 조성물 및 이의 용도
CN107683282A (zh)	2018-02-09	新型urat1抑制剂及其在医药上的应用
DD216019A5 (de)	1984-11-28	Verfahren zur herstellung heterocyclisch ankondensierter pyrazolo (3,4-d) pyridin-3-one
FI59253C (fi)	1981-07-10	Foerfarande foer framstaellning av terapeutiskt anvaendbara 4-hydroxi-2h-tieno(2,3-e) och (3,4-e)-1,2-tiazin-3-karboxamid-1,1-dioxid-derivat
SU1440349A3 (ru)	1988-11-23	Способ получени ортоконденсированных производных пиррола
DE2800596C2 (de)	1985-12-12	4,5,6,7-Tetrahydrothieno(2,3-c)- und -(3,2-c)pyridine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
CN101974015B (zh)	2012-05-09	酯类化合物、其制备方法和用途
CN105037252B (zh)	2018-05-04	N-取代-3,5-二(2-(三氟甲基)亚苄基)哌啶-4-酮衍生物及其制备方法与应用
EP4279074A1 (fr)	2023-11-22	Composés azolo pour le traitement de maladies fibrotiques
BR112017015597B1 (pt)	2023-02-28	Composto modulador do receptor da adenosina a3, composição farmacêutica, uso e combinação deste
CN101693718B (zh)	2011-10-19	含噻吩并吡啶的酯类衍生物、其制备方法和用途
US4187303A (en)	1980-02-05	Thiazine derivatives
CN104725372B (zh)	2017-02-22	四环吲哚生物碱衍生物及其制备和应用
CN119371402A (zh)	2025-01-28	螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途
HU186951B (en)	1985-10-28	Process for producing substitited thizaolo-bracket-3,2-a-bracket closed-parimidines and pharmaceutical compositions containing them
EP0292051A2 (fr)	1988-11-23	Dérivés de la thiénopyridine
CN102060792B (zh)	2016-08-03	2′-胺基查尔酮唑类化合物及其吡唑啉和环丙基唑类衍生物、制备方法与用途
CN104860900A (zh)	2015-08-26	噻唑类化合物、其制备方法及其在制药中的用途
CN111808079A (zh)	2020-10-23	吲哚类ask1小分子抑制剂及其制备方法和应用
CN114105986B (zh)	2024-09-27	一种芳香稠环二酮类化合物及其制备方法与应用